The Massachusetts medtech giant launches commercial efforts for its Polaris imaging software, an upgrade to the iLab system that aims to be "smart, fast and accurate."
Boston Scientific (NYSE:BSX) today announced the commercial launch of its Polaris imaging software, an upgrade to the company's iLab system that aims to make intravascular imaging simpler and more powerful.
DICOM Grid touts $6 million raised in an inside funding round in support of the company's cloud-based medical imaging management and exchange platform.
Vermont medical imaging services provider DICOM Grid today announced that it raised $6 million in an inside funding round, with investment coming from Canaan Partners, CHL Medical Partners, the Mayo Clinic and several individual investors.
Veran Medical is on a fundraising spree, adding another $6.5 million to its coffers in a $7.5 million round launches late last year.
Veran Medical Technologies is on the verge of closing yet another fundraising round in support of its electromagnetic airway mapping system, with just about $1 million to go.
Dune Medical aims to boost its sales & marketing efforts with $21 million in equity financing that it hopes to raise before October.
Israeli imaging systems maker Dune Medical Devices touted the successful raise of $14 million in equity financing, looking to secure another $7 million before October to support its commercialization efforts.
Lantheus Medical files registration forms ahead of an initial public offering worth up to $125 million in support of its diagnostic and imaging products.
Massachusetts-based Lantheus Medical Imaging announced today that it filed registration documents ahead of launching an initial public offering.
The company, which makes imaging agents and other diagnostic products, has yet to reveal share pricing or quantity, but set the maximum aggregate offering price at $125 million. Lantheus deals primarily in radiopharmaceutical and contrast agents, according to the prospectus summary.
The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body's head and neck region.
Ohio-based Navidea Biopharmaceuticals lands expanded FDA approval to market its Lymphoseek imaging agent for use in patients with cancers in the head and neck.
Navidea Biopharmaceuticals landed FDA approval to expand use for its Lymphoseek imaging agent to help track cancers spreading in the head and neck.
Lymphoseek is the "1st and only FDA-approved radiopharmaceutical application for sentinel lymph node detection," according to Navidea, which originally won FDA approval for Lymphoseek in March 2013.